Home‐Based Daratumumab in Patients With Multiple Myeloma
European Journal of Haematology · 2025-07 · 115 (1) · 72-81
DOI: 10.1111/ejh.14409 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift European Journal of Haematology, online erschienen am 31.03.2025. Verfasst von Tine Rosenberg und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology, Odense University Hospital, Odense, Denmark. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Antineoplastic Agents, Home Care Services, Multiple Myeloma. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Janssen-Cilag.
Abstract (Originalsprache)
Objective
Multiple myeloma is an incurable cancer with lifelong treatment needs. This, together with a global nursing shortage, calls for new approaches for future treatment. In this study, we therefore investigated the feasibility of home‐based subcutaneous daratumumab administered by primary care nurses outside the hospital.
Methods
Applying a mixed‐methods prospective design, we included 30 patients; 18 had completed ≥ 6 cycles of daratumumab treatment, and 12 were newly started. New patients were followed for six 28‐day cycles, with every second treatment administered outside the hospital. Patients already on treatment were followed for seven cycles with 2/3 treatments administered outside the hospital.
Results
Of 123 administrations planned at the hospital, 122 (97.6%) were administered and three were cancelled. Of 144 administrations planned outside the hospital, 133 (92.4%) were administered, six were redirected to the hospital, and five were cancelled. No significant difference between numbers of cancellations/redirections was observed. Patients spent significantly longer time on treatment at the hospital, even when deducting travel time. Reducing patients' visits to the hospital did not cause additional unplanned contacts with the healthcare system.
Conclusion
This study thus concludes that administration of daratumumab outside the hospital is safe, feasible, and time saving. Trial Registration: ClinicalTrials.gov ID: NCT05306587
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Haematology, Odense University Hospital, Odense, Denmark.
- Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
- Centre for Innovative Medical Technology, Odense University Hospital, Odense, Denmark.
- Department of Oncology, Odense University Hospital, Odense, Denmark.
ORCID-Profile: Tine Rosenberg, Jannie Kirkegaard, Michael Tveden Gundesen, Maja Kjær Rasmussen, Karin Brochstedt Dieperink, Thomas Lund
Förderung
- Janssen-Cilag
Zitieren
APA
Rosenberg, T., Kirkegaard, J., Gundesen, M. T., Rasmussen, M. K., Dieperink, K. B., & Lund, T. (2025). Home‐Based Daratumumab in Patients With Multiple Myeloma. European Journal of Haematology, 115(1), 72-81. https://doi.org/10.1111/ejh.14409
Vancouver
Rosenberg T, Kirkegaard J, Gundesen MT, Rasmussen MK, Dieperink KB, Lund T. Home‐Based Daratumumab in Patients With Multiple Myeloma. European Journal of Haematology. 2025;115(1):72-81. doi:10.1111/ejh.14409
BibTeX
@article{Rosenberg2025,
author = {Rosenberg, Tine and Kirkegaard, Jannie and Gundesen, Michael Tveden and Rasmussen, Maja Kjær and Dieperink, Karin Brochstedt and Lund, Thomas},
title = {Home‐Based Daratumumab in Patients With Multiple Myeloma},
journal = {European Journal of Haematology},
year = {2025},
volume = {115},
number = {1},
pages = {72--81},
doi = {10.1111/ejh.14409}
}
EUVIMED